Hypermethylation of the DAP-Kinase CpG island is a common alteration in B-cell malignancies

被引:290
|
作者
Katzenellenbogen, RA [1 ]
Baylin, SB [1 ]
Herman, JG [1 ]
机构
[1] Johns Hopkins Comprehens Canc Ctr, Baltimore, MD USA
关键词
D O I
10.1182/blood.V93.12.4347.412k31_4347_4353
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Death-associated protein kinase (DAP-Kinase) is a novel serine/threonine kinase whose expression is required for gamma interferon-induced apoptosis, A previous study suggested that DAP-Kinase expression may be lost epigenetically in cancer cell lines, because treatment of several nonexpressing cell lines with 5-aza-2'-deoxycytidine resulted in the expression of DAP-Kinase, Using methylation-specific polymerase chain reaction (MSP), we examined the DAP-Kinase CpG island for hypermethylation in cancer. Normal lymphocytes and lymphoblastoid cell lines are unmethylated in the 5' CpG island of DAP-Kinase. However, in primary tumor samples, all Burkitt's lymphomas and 84% of the B-cell non-Hodgkin's lymphomas were hypermethylated in the DAP-Kinase CpG island. In contrast, none of the T-cell non-Hodgkin's lymphoma samples and 15% or less of leukemia samples examined had hypermethylated DAP-Kinase alleles. U937, an unmethylated, DAP-Kinase-expressing leukemia cell line, was treated with gamma interferon and underwent apoptosis; however, Raji, a fully methylated, DAP-Kinase nonexpressing Burkitt's lymphoma cell line, only did so when treated with 5-aza-2'-deoxycytidine followed by gamma interferon, Our findings in cell lines and primary tumors suggest that hypermethylation of the DAP-Kinase gene and loss of gamma interferon-mediated apoptosis may be important in the development of B-cell malignancies and may provide a promising biomarker for B-cell-lineage lymphomas. (C) 1999 by The American Society of Hematology.
引用
收藏
页码:4347 / 4353
页数:7
相关论文
共 50 条
  • [41] Zanubrutinib in B-cell malignancies
    Das, Manjulika
    [J]. LANCET ONCOLOGY, 2019, 20 (09): : E470 - E470
  • [42] Obinutuzumab for B-cell malignancies
    Owen, Carolyn J.
    Stewart, Douglas A.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (08) : 1197 - 1205
  • [43] Neurotrophins and B-cell malignancies
    Jennifer Hillis
    Michael O’Dwyer
    Adrienne M. Gorman
    [J]. Cellular and Molecular Life Sciences, 2016, 73 : 41 - 56
  • [44] Autoimmunity and B-cell malignancies
    Dighiero, G
    [J]. HEMATOLOGY AND CELL THERAPY, 1998, 40 (01): : 1 - 9
  • [45] Neurotrophins and B-cell malignancies
    Hillis, Jennifer
    O'Dwyer, Michael
    Gorman, Adrienne M.
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2016, 73 (01) : 41 - 56
  • [46] Hypermethylation of the 5′CpG island of the FHIT gene in clear cell renal carcinomas
    Kvasha, Sergiy
    Gordiyuk, Vasily
    Kondratov, Alexandr
    Ugryn, Dmytro
    Zgonnyk, Yury M.
    Rynditch, Alla V.
    Vozianov, Alexandr F.
    [J]. CANCER LETTERS, 2008, 265 (02) : 250 - 257
  • [47] DAP-kinase is a mediator of endoplasmic reticulum stress-induced caspase activation and autophagic cell death
    D Gozuacik
    S Bialik
    T Raveh
    G Mitou
    G Shohat
    H Sabanay
    N Mizushima
    T Yoshimori
    A Kimchi
    [J]. Cell Death & Differentiation, 2008, 15 : 1875 - 1886
  • [48] Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features
    Shirley, Matt
    [J]. TARGETED ONCOLOGY, 2022, 17 (01) : 69 - 84
  • [49] B-CELL MALIGNANCIES FREQUENTLY TARGET THE AUTOREACTIVE B-CELL REPERTOIRE
    DIGHIERO, G
    BORCHE, L
    [J]. LEUKEMIA & LYMPHOMA, 1991, 5 : 47 - 51
  • [50] Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies
    Lucas, Fabienne
    Woyach, Jennifer A.
    [J]. TARGETED ONCOLOGY, 2019, 14 (02) : 125 - 138